Revised SPC: Ozempic (semaglutide) 0.25 mg solution for injection in pre-filled pen

The SPC now lists acute pancreatitis as an uncommon adverse event, and notes that diabetic ketoacidosis has been reported in insulin-dependent patients whom had rapid discontinuation or dose reduction of insulin when treatment with a GLP-1 receptor agonist is started.


electronic Medicines compendium